Comments

VYNE Therapeutics

VYNENASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$2.25
0.020.90%
At Close: -
$2.23
-0.02-0.89%
After Hours: Jul 16, 4:00 PM EDT
15 minutes delayed
VYNE Therapeutics (VYNE) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Overweight
Highest Price Target1
$9.00
Lowest Price Target1
$5.75
Consensus Price Target1
$7.38

want to know what
the Bulls & Bears Say?

VYNE Therapeutics (NASDAQ:VYNE) Stock, Analyst Ratings, Price Targets, Forecasts

VYNE Therapeutics Inc has a consensus price target of $7.38 based on the ratings of 2 analysts. The high is $9 issued by Cantor Fitzgerald on May 12, 2023. The low is $5.75 issued by HC Wainwright & Co. on June 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 14, 2024, June 5, 2024, and May 9, 2024, respectively. With an average price target of $5.75 between HC Wainwright & Co., there's an implied 157.85% upside for VYNE Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Cantor Fitzgerald

1calculated from analyst ratings

Analyst Ratings for VYNE Therapeutics

Buy NowGet Alert
06/14/2024Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
$5.75 → $5.75ReiteratesBuy → BuyGet Alert
06/05/2024Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
$5.75 → $5.75ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
 → $5.75ReiteratesBuy → BuyGet Alert
05/06/2024Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
 → $5.75ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
—ReiteratesBuy → BuyGet Alert
10/30/2023Buy Now157.85%HC Wainwright & Co.
Joseph Pantginis
$28 → $5.75MaintainsBuyGet Alert
08/14/2023Buy Now1155.61%HC Wainwright & Co.
Joseph Pantginis
$28 → $28ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now303.59%Cantor Fitzgerald
Louise Chen
$5 → $9MaintainsOverweightGet Alert
05/12/2023Buy Now1155.61%HC Wainwright & Co.
Joseph Pantginis
 → $28ReiteratesBuy → BuyGet Alert
04/19/2023Buy Now1155.61%HC Wainwright & Co.
Joseph Pantginis
 → $28Reiterates → BuyGet Alert
03/30/2023Buy Now1155.61%HC Wainwright & Co.
Joseph Pantginis
$1.5 → $28Reiterates → BuyGet Alert
03/14/2023Buy Now1155.61%HC Wainwright & Co.
Joseph Pantginis
$1.5 → $28Reiterates → BuyGet Alert
08/10/2022Buy Now-32.74%HC Wainwright & Co.
Joseph Pantginis
$126 → $27MaintainsBuyGet Alert
12/06/2021Buy Now213.9%HC Wainwright & Co.
Joseph Pantginis
 → $126Assumes → BuyGet Alert

FAQ

Q

What is the target price for VYNE Therapeutics (VYNE) stock?

A

The latest price target for VYNE Therapeutics (NASDAQ:VYNE) was reported by HC Wainwright & Co. on June 14, 2024. The analyst firm set a price target for $5.75 expecting VYNE to rise to within 12 months (a possible 157.85% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for VYNE Therapeutics (VYNE)?

A

The latest analyst rating for VYNE Therapeutics (NASDAQ:VYNE) was provided by HC Wainwright & Co., and VYNE Therapeutics reiterated their buy rating.

Q

When was the last upgrade for VYNE Therapeutics (VYNE)?

A

There is no last upgrade for VYNE Therapeutics

Q

When was the last downgrade for VYNE Therapeutics (VYNE)?

A

There is no last downgrade for VYNE Therapeutics.

Q

When is the next analyst rating going to be posted or updated for VYNE Therapeutics (VYNE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VYNE Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VYNE Therapeutics was filed on June 14, 2024 so you should expect the next rating to be made available sometime around June 14, 2025.

Q

Is the Analyst Rating VYNE Therapeutics (VYNE) correct?

A

While ratings are subjective and will change, the latest VYNE Therapeutics (VYNE) rating was a reiterated with a price target of $5.75 to $5.75. The current price VYNE Therapeutics (VYNE) is trading at is $2.23, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch